- Home
- C vs BMY Comparison
C vs BMY Comparison
Compare C & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- C
- BMY
- Stock Information
- Founded
- C 1812
- BMY 1887
- Country
- C United States
- BMY United States
- Employees
- C N/A
- BMY N/A
- Industry
- C Major Banks
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- C Finance
- BMY Health Care
- Exchange
- C Nasdaq
- BMY Nasdaq
- Market Cap
- C 137.4B
- BMY 120.4B
- IPO Year
- C N/A
- BMY N/A
- Fundamental
- Price
- C $69.22
- BMY $57.28
- Analyst Decision
- C Buy
- BMY Hold
- Analyst Count
- C 15
- BMY 15
- Target Price
- C $76.60
- BMY $55.93
- AVG Volume (30 Days)
- C 14.2M
- BMY 11.6M
- Earning Date
- C 01-15-2025
- BMY 02-06-2025
- Dividend Yield
- C 3.24%
- BMY 4.33%
- EPS Growth
- C N/A
- BMY N/A
- EPS
- C 3.48
- BMY N/A
- Revenue
- C $69,308,000,000.00
- BMY $47,435,000,000.00
- Revenue This Year
- C N/A
- BMY $7.22
- Revenue Next Year
- C $2.30
- BMY $0.16
- P/E Ratio
- C $19.85
- BMY N/A
- Revenue Growth
- C N/A
- BMY 5.56
- 52 Week Low
- C $50.51
- BMY $39.35
- 52 Week High
- C $73.38
- BMY $61.08
- Technical
- Relative Strength Index (RSI)
- C 47.41
- BMY 50.79
- Support Level
- C $67.92
- BMY $55.04
- Resistance Level
- C $71.47
- BMY $58.55
- Average True Range (ATR)
- C 1.46
- BMY 1.28
- MACD
- C -0.58
- BMY -0.31
- Stochastic Oscillator
- C 23.81
- BMY 44.36
About C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.